Every material Form 8-K Anika Therapeutics, Inc. has filed with the SEC since June 23, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Anika Therapeutics reported third-quarter 2026 revenue of $30.6 million, up 10% from a year earlier, and a narrower GAAP loss from continuing operations of $0.3 million. It raised the low end of its 2026 total revenue guidance and its 2026 adjusted EBITDA margin guidance, but cut its Commercial Channel growth guidance. In October, the FDA said the Hyalofast application is not approvable, which removes a near-term regulatory path for that product.
Revenue was $30.6 million versus $27.8 million; Commercial Channel rose 17% to $14.0 million and OEM Channel rose 5% to $16.6 million.
GAAP loss from continuing operations was $0.3 million, or $0.02 per diluted share, versus $3.2 million a year earlier; adjusted EBITDA was $5.1 million versus $0.9 million.
2026 total revenue growth guidance is now 6% to 10%, up from 5% to 10%; Commercial Channel guidance was cut to 9% to 13% from 12% to 18%.
In October, the FDA informed Anika that the Hyalofast pre-market approval application is not approvable, primarily based on the clinical data submitted.
Anika Therapeutics reported second-quarter 2026 revenue of $32.6 million, up 16% from a year earlier, and net income of $3.3 million, compared with a net loss of $4.0 million in the prior-year quarter. The company raised its 2026 revenue and adjusted EBITDA margin guidance, but cut its 2027 Commercial Channel revenue forecast and removed Hyalofast revenue from that forecast pending FDA approval.
Q2 2026 revenue was $32.6 million, up from $28.2 million in Q2 2025; Commercial Channel revenue was a record $13.9 million.
Q2 2026 net income was $3.3 million, or $0.24 per diluted share, versus a net loss of $4.0 million a year earlier.
2026 revenue growth guidance raised to 5% to 10% from 1% to 9%; adjusted EBITDA margin guidance raised to 13% to 17% from 5% to 10%.
2027 Commercial Channel revenue growth guidance lowered to 5% to 15% from 10% to 20%, excluding Hyalofast, which is still under FDA review.
Anika Therapeutics entered into a Fifth Amendment to its revolving credit agreement with Bank of America, N.A., extending the senior revolving line of credit to a $50.0 million facility maturing July 10, 2031. The company may request up to an additional $50.0 million in commitments, for a maximum of $100.0 million, subject to lender approval. The filing does not report any borrowings under the facility, and the amendment adds lender liens on substantially all assets and financial covenants that shareholders should note.
Senior revolving line of credit of $50.0 million, maturing July 10, 2031, with an option for up to $100.0 million aggregate commitments
Interest at SOFR plus 0.25% to 1.25%, based on the consolidated leverage ratio; commitment fee of 0.20% to 0.30% per annum on unused amounts
Lenders have a first priority lien on substantially all assets, except certain intangible assets; covenants cover leverage and interest coverage ratios
Amendment dated July 10, 2026; 8-K filed July 14, 2026 with Exhibit 10.1 attached
At its June 18, 2026 annual meeting, Anika Therapeutics stockholders approved an increase of 350,000 shares to the 2017 Omnibus Incentive Plan, raising the reserve from 5,760,000 to 6,110,000 shares, and a 200,000-share increase to the 2021 Employee Stock Purchase Plan, raising its reserve to 400,000 shares. The votes also re-elected three Class III directors and ratified Deloitte & Touche LLP as the independent auditor for fiscal 2026, so shareholders should note the larger pool of shares available for future grants and purchases.
Annual meeting held June 18, 2026; shares representing 84.14% of the voting power entitled to vote were present in person or by proxy.
Revised Seventh Amended Plan approved with 8,013,994 votes for and 1,347,970 against; reserve rises from 5,760,000 to 6,110,000 shares.
ESPP amendment approved with 9,110,892 votes for and 257,394 against; reserve rises from 200,000 to 400,000 shares.
Gary P. Fischetti, John B. Henneman, III and Stephen D. Griffin elected as Class III directors to serve until the 2029 annual meeting.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Anika Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →